Oral glycoprotein IIb/IIIa antagonists: New insights from the SYMPHONY trial

Darren K McGuire, L. K. Newby

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

Platelet aggregation plays a central role in the pathophysiology of acute coronary syndromes, and the platelet glycoprotein IIb/IIIa receptor has been identified as the critical final mediator of this process. Antagonists of this receptor used parenterally during both acute coronary syndromes and percutaneous coronary interventions reduce the likelihood of subsequent major cardiac complications. However, after the treatment period little further benefit accrues. Based on these observations and that of the significant benefit of aspirin in cardiovascular secondary prevention, oral glycoprotein IIb/IIIa receptor antagonists are being evaluated with the goal of extending the benefit of glycoprotein IIb/IIIa inhibition into chronic secondary prevention. This paper will review the results of the SYMPHONY study of one such oral agent, sibrafiban, and the current state of the oral glycoprotein IIb/IIIa inhibitor field.

Original languageEnglish (US)
Pages (from-to)111-119
Number of pages9
JournalJournal of Thrombosis and Thrombolysis
Volume10
Issue number2
StatePublished - 2000

Fingerprint

Platelet Glycoprotein GPIIb-IIIa Complex
Acute Coronary Syndrome
Secondary Prevention
Integrin beta3
Percutaneous Coronary Intervention
Platelet Aggregation
Aspirin
Therapeutics

Keywords

  • Coronary artery disease
  • Glycoprotein IIb/IIIa inhibitors
  • Platelet aggregation inhibitors
  • Platelets
  • Secondary prevention

ASJC Scopus subject areas

  • Hematology
  • Cardiology and Cardiovascular Medicine

Cite this

Oral glycoprotein IIb/IIIa antagonists : New insights from the SYMPHONY trial. / McGuire, Darren K; Newby, L. K.

In: Journal of Thrombosis and Thrombolysis, Vol. 10, No. 2, 2000, p. 111-119.

Research output: Contribution to journalArticle

@article{1793cfaaa6df4c6e8a15aba113354e43,
title = "Oral glycoprotein IIb/IIIa antagonists: New insights from the SYMPHONY trial",
abstract = "Platelet aggregation plays a central role in the pathophysiology of acute coronary syndromes, and the platelet glycoprotein IIb/IIIa receptor has been identified as the critical final mediator of this process. Antagonists of this receptor used parenterally during both acute coronary syndromes and percutaneous coronary interventions reduce the likelihood of subsequent major cardiac complications. However, after the treatment period little further benefit accrues. Based on these observations and that of the significant benefit of aspirin in cardiovascular secondary prevention, oral glycoprotein IIb/IIIa receptor antagonists are being evaluated with the goal of extending the benefit of glycoprotein IIb/IIIa inhibition into chronic secondary prevention. This paper will review the results of the SYMPHONY study of one such oral agent, sibrafiban, and the current state of the oral glycoprotein IIb/IIIa inhibitor field.",
keywords = "Coronary artery disease, Glycoprotein IIb/IIIa inhibitors, Platelet aggregation inhibitors, Platelets, Secondary prevention",
author = "McGuire, {Darren K} and Newby, {L. K.}",
year = "2000",
language = "English (US)",
volume = "10",
pages = "111--119",
journal = "Journal of Thrombosis and Thrombolysis",
issn = "0929-5305",
publisher = "Springer Netherlands",
number = "2",

}

TY - JOUR

T1 - Oral glycoprotein IIb/IIIa antagonists

T2 - New insights from the SYMPHONY trial

AU - McGuire, Darren K

AU - Newby, L. K.

PY - 2000

Y1 - 2000

N2 - Platelet aggregation plays a central role in the pathophysiology of acute coronary syndromes, and the platelet glycoprotein IIb/IIIa receptor has been identified as the critical final mediator of this process. Antagonists of this receptor used parenterally during both acute coronary syndromes and percutaneous coronary interventions reduce the likelihood of subsequent major cardiac complications. However, after the treatment period little further benefit accrues. Based on these observations and that of the significant benefit of aspirin in cardiovascular secondary prevention, oral glycoprotein IIb/IIIa receptor antagonists are being evaluated with the goal of extending the benefit of glycoprotein IIb/IIIa inhibition into chronic secondary prevention. This paper will review the results of the SYMPHONY study of one such oral agent, sibrafiban, and the current state of the oral glycoprotein IIb/IIIa inhibitor field.

AB - Platelet aggregation plays a central role in the pathophysiology of acute coronary syndromes, and the platelet glycoprotein IIb/IIIa receptor has been identified as the critical final mediator of this process. Antagonists of this receptor used parenterally during both acute coronary syndromes and percutaneous coronary interventions reduce the likelihood of subsequent major cardiac complications. However, after the treatment period little further benefit accrues. Based on these observations and that of the significant benefit of aspirin in cardiovascular secondary prevention, oral glycoprotein IIb/IIIa receptor antagonists are being evaluated with the goal of extending the benefit of glycoprotein IIb/IIIa inhibition into chronic secondary prevention. This paper will review the results of the SYMPHONY study of one such oral agent, sibrafiban, and the current state of the oral glycoprotein IIb/IIIa inhibitor field.

KW - Coronary artery disease

KW - Glycoprotein IIb/IIIa inhibitors

KW - Platelet aggregation inhibitors

KW - Platelets

KW - Secondary prevention

UR - http://www.scopus.com/inward/record.url?scp=0033754471&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0033754471&partnerID=8YFLogxK

M3 - Article

C2 - 11005932

AN - SCOPUS:0033754471

VL - 10

SP - 111

EP - 119

JO - Journal of Thrombosis and Thrombolysis

JF - Journal of Thrombosis and Thrombolysis

SN - 0929-5305

IS - 2

ER -